Clinical Study
Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance
Table 1
Baseline characteristics of study patients and frequencies of medication usage before admission.
| | | Control group
() | Acarbose group
() | value |
| | Basic characteristic | | | | | Age, year | 61.62 ± 4.58 | 62.24 ± 5.16 | 0.461 | | Male, (%) | 42 (61.76) | 39 (58.21) | 0.673 | | Smoking, (%) | 31 (45.59) | 28 (41.79) | 0.657 | | AMI, (%) | 43 (63.24) | 46 (68.66) | 0.506 | | Hypertension, (%) | 46 (67.65) | 45 (67.16) | 0.637 | | LVEF, % | 52.13 ± 4.81 | 51.74 ± 5.25 | 0.653 | | Revascularization (PCI/CABG), (%) | 38 (55.88) | 41 (61.19) | 0.531 | | BMI, kg/m2 | 25.82 ± 2.45 | 26.05 ± 3.24 | 0.427 | | Medications | | | | | -blocker, (%) | 16 (23.53) | 13 (19.40) | 0.559 | | ACE-I/ARB, (%) | 47 (69.12) | 45 (67.16) | 0.808 | | CCB, (%) | 18 (26.47) | 20 (29.85) | 0.662 | | Statin, (%) | 63 (92.65) | 61 (91.04) | 0.734 | | Aspirin, (%) | 64 (94.12) | 62 (92.54) | 0.713 |
|
|
AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; BMI: body mass index; ACE-I: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CCB: calcium channel blocker.
|
